Results 161 to 170 of about 24,145,261 (292)

CAR‐HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar, David Tucker, Tae Min Kim, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Manjusha Namuduri, Aafia Chaudhry, Stefano Luminari   +9 more
wiley   +1 more source

Primary Prostatic Diffuse Large B-Cell Lymphoma Mimicking Prostate Cancer With a Normal Prostate-Specific Antigen Level. [PDF]

IJU Case Rep
Amamoto K, Nakamura Y, Fukushima H, Harada J, Matsuda T, Ito I, Mitsunari K, Matsuo T, Ohba K, Imamura R.   +9 more
europepmc   +1 more source

A B-cell lymphoma case that is unclassifiable, and intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma of lacrimal gland

, 2017
Tatsuya Yunoki,1 Jun Murakami,2 Yukihiro Imagawa,3 Takahiko Nakajima,4 Atsushi Hayashi1 1Department of Ophthalmology, 2Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, 3Department of ...
Murakami J, Nakajima T, Yunoki T, Hayashi A, Imagawa Y   +4 more
core  

Ibrutinib and standard immunochemotherapy in younger, high‐risk patients with diffuse large B‐cell lymphoma: A phase II study of GLA

British Journal of Haematology, EarlyView.
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov, Marita Ziepert, Birte Friedrichs, Susanne Ghandili, Kai Wille, Bertram Glass, Maike Nickelsen, Peter Borchmann, Andreas Viardot, Andrea Kerkhoff, Philipp Berning, Sebastian Böttcher, Stefan Wirths, Tobias Kewitz, Mathias Hänel, Judith Dierlamm, Andreas Rosenwald, Bettina Altmann, Georg Lenz, Norbert Schmitz   +19 more
wiley   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

British Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee, Eric J. Zhao, Cassidy Clemente‐Jones, Rebecca J. Deyell, Shahrad R. Rassekh, Anita Villani, Rosemarie Venier, Daniel Sinnett, Sylvie Langlois, Thai Hoa Tran, Thomas Sontag, Stephanie Grover, Scott Davidson, Nisha Kanwar, Winnie Lo, Erin Pleasance, Laura Williamson, Yaoqing Shen, Alina S. Gerrie, Kerry J. Savage, Laurie H. Sehn, Christopher P. Venner, Marco A. Marra, Janessa Laskin, Diego Villa   +24 more
wiley   +1 more source

Baseline maximum standardised uptake value does not predict outcomes in high‐tumour‐burden follicular lymphoma treated with first‐line immunochemotherapy

British Journal of Haematology, EarlyView.
Baseline maximum standardised uptake value does not predict survival in high‐tumour‐burden follicular lymphoma treated with first‐line immunochemotherapy, but identifies patients at risk of histological transformation: no transformation occurred below the cohort median. Its role is to guide biopsy and surveillance rather than therapeutic stratification.
Ikram Bouguern, Zora Marjanovic, Elise Corre, Laure Ricard, Bénédicte Jonca, Fazia Kaoui, Zoé Van de Wyngaert, Paul Coppo, Mohamad Mohty, Florent Malard, Nicolas Stocker   +10 more
wiley   +1 more source

Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type, With Rapid Systemic Progression in an Elderly Patient: A Case Report. [PDF]

Cureus
Solorio Rivera AH, Limon Limon MF, Sol BS, Sierra Franco A, Sanroman Loza EA.   +4 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Diffuse Large B-Cell Lymphoma Presenting as a Rapidly Enlarging Forehead Mass Initially Suggestive of a Subgaleal Hematoma: A Case Report. [PDF]

Clin Case Rep
Yonenaga A, Isono N, Higashiyama A, Tsukada M, Hori K.   +4 more
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source